Monolithic Power Systems Inc vs Twist Bioscience Corp — how do they compare? Monolithic Power Systems Inc trades at $1,381.5 (market cap $65.28B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Monolithic Power Systems Inc is far larger — about 12× Twist Bioscience Corp's market cap, and Monolithic Power Systems Inc pays a 0.6% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| MPWR | TWST | |
|---|---|---|
Market Cap | $65.28B | $5.45B |
Sector | Utilities | Health |
52-Week High | $1.69K | $102.88 |
52-Week Low | $711.24 | $24.16 |
Enterprise Value | $63.94B | $5.37B |
Dividend Yield | 0.6% | — |
Signals from Pluang's Aura AI — not financial advice
MPWR trades at $1,328.80, up 1.28% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a 22.98% net margin and robust cash flow, but carries high valuation multiples like a P/E of 93.92. Analyst consensus is overwhelmingly bullish with an $1,810 price target, though news includes both AI infrastructure optimism and legal investigations.
Outlook remains positive given earnings momentum and AI-driven demand, but risks include stretched valuations and ongoing legal scrutiny. The stock offers growth exposure but requires monitoring of execution and market sentiment shifts.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →